Zerviate (Cetirizine HCl) Patent Expiration, LOE Window & CMS Spending

Zerviate (Cetirizine HCl) by Harrow Eye: FDA Orange Book LOE 2033-01-09, 0 AB generics, $4.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN208694 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-01-09
Orange Book Patents (*PED Extensions)6 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.4M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$524K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel